Movement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts

Market Focus13:12

On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of decline totaling over 10%, during which it touched a 52-week low of 22.90 HKD.

On the news front, the rebound was driven by oversold technical recovery combined with multiple positive catalysts. The company was recently included in the MSCI Global Index, with passive fund rebalancing selling pressure now largely digested following the effective date on May 29. Additionally, China Post Securities initiated coverage with a Buy rating, citing the company entering its commercialization phase with its first product SJ02 approved in August last year and core product KJ017 approved in March this year as China's first approved recombinant human hyaluronidase. The appointment of new Chairman Liu Yanjun has also provided governance stability.

The stock had previously plunged 65% in late April and had been consolidating at depressed levels. With selling pressure from index rebalancing absorbed, the market appears to be entering a confidence recovery phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154040634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 13:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154040634","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts","media":"Market Focus","content":"<p><p>On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of decline totaling over 10%, during which it touched a 52-week low of 22.90 HKD.</p><p>On the news front, the rebound was driven by oversold technical recovery combined with multiple positive catalysts. The company was recently included in the MSCI Global Index, with passive fund rebalancing selling pressure now largely digested following the effective date on May 29. Additionally, China Post Securities initiated coverage with a Buy rating, citing the company entering its commercialization phase with its first product SJ02 approved in August last year and core product KJ017 approved in March this year as China's first approved recombinant human hyaluronidase. The appointment of new Chairman Liu Yanjun has also provided governance stability.</p><p>The stock had previously plunged 65% in late April and had been consolidating at depressed levels. With selling pressure from index rebalancing absorbed, the market appears to be entering a confidence recovery phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Baoji Pharma-B Rises 13.37% in Regular Trading, Oversold Rebound After Hitting 52-Week Low Amid Multiple Positive Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 13:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of decline totaling over 10%, during which it touched a 52-week low of 22.90 HKD.</p><p>On the news front, the rebound was driven by oversold technical recovery combined with multiple positive catalysts. The company was recently included in the MSCI Global Index, with passive fund rebalancing selling pressure now largely digested following the effective date on May 29. Additionally, China Post Securities initiated coverage with a Buy rating, citing the company entering its commercialization phase with its first product SJ02 approved in August last year and core product KJ017 approved in March this year as China's first approved recombinant human hyaluronidase. The appointment of new Chairman Liu Yanjun has also provided governance stability.</p><p>The stock had previously plunged 65% in late April and had been consolidating at depressed levels. With selling pressure from index rebalancing absorbed, the market appears to be entering a confidence recovery phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1154040634","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154040634","pubTimestamp":1780549973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"动向提示|宝鸡医药-B常规交易涨13.37%多重利好催化下创52周新低后超跌反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of decline totaling over 10%, during which it touched a 52-week low of 22.90 HKD.On the news front, the rebound was driven by oversold technical recovery combined with multiple positive catalysts. The company was recently included in the MSCI Global Index, with passive fund rebalancing selling pressure now largely digested following the effective date on May 29. Additionally, China Post Securities initiated coverage with a Buy rating, citing the company entering its commercialization phase with its first product SJ02 approved in August last year and core product KJ017 approved in March this year as China's first approved recombinant human hyaluronidase. The appointment of new Chairman Liu Yanjun has also provided governance stability.The stock had previously plunged 65% in late April and had been consolidating at depressed levels. With selling pressure from index rebalancing absorbed, the market appears to be entering a confidence recovery phase.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154040634","isCrawlerRequest":true}